A post to the site of the U.S. Patent and Trademark Office stated: "Liquidia Technologies (LQDA), the "Petitioner," filed a Petition requesting an inter partes review of claims 1-8 of U.S. Patent No. 10,716,793 B2, "the ‘793 patent." United Therapeutics (UTHR), the "Patent Owner," filed a Preliminary Response… On August 11, 2021, we instituted inter partesreview of claims 1-8 of the ‘793 patent on all grounds set forth in the Petition… On July 19, 2022, we issued a Final Written Decision determining that Petitioner had proven by a preponderance of evidence that all the challenged claims were unpatentable… On August 18, 2022, Patent Owner requested rehearing and filed a request that rehearing be conducted by the Precedential Opinion Panel… For the reasons discussed below, we deny Patent Owner’s Request for Rehearing. Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on UTHR: